Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP228408.RAzyv-OPFvX0QzodzhqV8x25yXYf94Idn81SL7WsvQDlM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP228408.RAzyv-OPFvX0QzodzhqV8x25yXYf94Idn81SL7WsvQDlM130_assertion type Assertion NP228408.RAzyv-OPFvX0QzodzhqV8x25yXYf94Idn81SL7WsvQDlM130_head.
- NP228408.RAzyv-OPFvX0QzodzhqV8x25yXYf94Idn81SL7WsvQDlM130_assertion description "[Before therapy, in comparison with the control group, levels of left ventricular end diastolic diameter, NT-proBNP, C-reactive protein (CRP), Th1, Th1/Th2, IFN-?, and T-bet mRNA and T-bet/GATA-3 mRNA all increased, and the level of left ventricular ejection fraction (LVEF), 6MWT, Th2, IL-4, and GATA-3 mRNA also decreased in both the CCI intervention and control groups.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP228408.RAzyv-OPFvX0QzodzhqV8x25yXYf94Idn81SL7WsvQDlM130_provenance.
- NP228408.RAzyv-OPFvX0QzodzhqV8x25yXYf94Idn81SL7WsvQDlM130_assertion evidence source_evidence_literature NP228408.RAzyv-OPFvX0QzodzhqV8x25yXYf94Idn81SL7WsvQDlM130_provenance.
- NP228408.RAzyv-OPFvX0QzodzhqV8x25yXYf94Idn81SL7WsvQDlM130_assertion SIO_000772 23413906 NP228408.RAzyv-OPFvX0QzodzhqV8x25yXYf94Idn81SL7WsvQDlM130_provenance.
- NP228408.RAzyv-OPFvX0QzodzhqV8x25yXYf94Idn81SL7WsvQDlM130_assertion wasDerivedFrom befree-20140225 NP228408.RAzyv-OPFvX0QzodzhqV8x25yXYf94Idn81SL7WsvQDlM130_provenance.
- NP228408.RAzyv-OPFvX0QzodzhqV8x25yXYf94Idn81SL7WsvQDlM130_assertion wasGeneratedBy ECO_0000203 NP228408.RAzyv-OPFvX0QzodzhqV8x25yXYf94Idn81SL7WsvQDlM130_provenance.